Revance Therapeutics, Inc.

DAXXIFY

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Revance Therapeutics, Inc.

Daxxify HCPCS:

C9160

HCPCS Code Descriptor:

Injection, daxibotulinumtoxina-lanm, 1 unit

Category:

C Code

Daxxify NDCs:

No actively aligned NDCs found

Primary Type:

Botulinum Toxin

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Intramuscular

Daxxify CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Daxxify:

DAXXIFY is a Botulinum Toxin drug manufactured by Revance Therapeutics, Inc. and administered via the Intramuscular route of administration. The C Code: C9160 is aligned to the drug DAXXIFY.

ACCESS PRICING AND MORE BY REGISTERING

C9160 Added Date:

January 1, 2024

C9160 Effective Date:

January 1, 2024

C9160 Termination Date:

April 1, 2024

We have not yet identified a manufacturer source of Daxxify billing and coding information.
Our team did not identify a source for Daxxify patient assistance information. Please reach out to our team if you feel that this is a mistake.
DAXXIFY prescribing information can be found at the link below:
Information regarding DAXXIFY’s side effects can be found at MedlinePlus